 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] NKMAX announced on the 7th that it has signed an LOC with China's medical and health service company Shoukang Group to attract large-scale investment.
Shoukang Group will invest $ 50 million in NKMax. The type of investment is third-party allocation paid-in capital increase.
Through this large-scale investment, NKmax plans to distribute various products such as NK cell therapy (SNK) business, immune diagnosis kit (NK view kit), and health functional food to the global market.
The Shoukang Group has a global sales and distribution network in China, the US, Europe and Asia, and has years of business experience and data in medical and health services.
In addition, it has partnered with Jingdong.com, the No. 1 e-commerce company in China, to jointly sell various health functional foods and medical consumables.
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
